Summary
The in situ perfused rat pancreas of normal and hypersomatotropic rats was used to study the effects of serotonin and its antagonists on the release of insulin in the presence of 4.4 mM and 16.6 mM glucose. In normal rats, serotonin (1.0 x lO-sM and 2.3 x 10-4M) inhibited significantly the glucosemediated first phase of insulin release but did not affect the basal release of insulin (4.4 mM glucose). The serotonin antagonists methysergide maleate (MSM) (1.0 x IO-4M), Squibb (SQ) 10,631 (SQ (l.0 x 10-4M) and cyproheptadine (Cy) (2.8 x 1O-9M) blocked the inhibitory action of serotonin. Only MSM potentiated the glucose-media ted first phase of insulin release in the presence and absence of serotonin. At this dose, MSM and SQ each significantly stimulated insulin release in the presence of non-stimulatory glucose concentration (4.4 mM).
In hypersomatotropic rats, serotonin inhibited the first phase of glucose-media ted insulin release, but a 20-times higher concentration than that used in normal rats was necessary to obtain the same degree of inhibition. In contrast the antagonists MSM, SQ and Cy did not block the inhibition induced by serotonin. MSM and SQ, however, significantly stimulated insu-!in release in the presence of 4.4 mM glucose. The results obtained suggest that: *Presented in part to the 59th Annual Meeting of the Federation of American Societies for Experimental Biology, April 13-19,1975 , Atlantic City, New Jersey. **Supported by Grant MA-2086 from the Medical Research Council of Canada.
Introduction
Investigations to date on a possible role of serotonin (S-HT) on the mechanism of insulin release is still a matter of discussion. Indeed, it has been reported that S-HT inhibits the glucose-mediated insulin release in the golden hamster (Feldman and Lebovitz 1970a; Feldman and Lebovitz 1970b) , stimulates the release of insulin in rabbits (Te/ib, Raptis, Schräder and Pfeiffer 1968) , rats (Gagliardino, Zieher, ltu"iza, Hernandez and Rodriguez 1971) and mice (Gagliardino, Nierle and Pfeiffer 1974) while others found that in mice 5-HT inhibits (Lundquist, Ekholm and Ericson 1971) or showed no effect (Feldman and Lebovitz 1970b) upon insulin release.
Evidence has accumulated suggesting that S-HT may play an important role modulating the release of insulin. The serotonin antagonists methysergide maleate (MSM), cyproheptadine (Cy) and cinaserin were shown to potentiate the in vitra glucose-mediated insulin release in the golden hamster (Feldman, Quickel Jr. and Lebovitz 1972) . MSM appeared to improve the overall insulin release in response to glucose challenge in maturity onset diabetic patients (Quickel Jr., Feldman and Lebovitz 1971) . Recently, Feldman, Plonk, Bivens and Lebovitz (1975) reported that the impaired insulin release observed in patients with the carcinoid syndrome was mainly due to the high circulating serotonin levels. In these patients, the early peak of insulin release appeared blunted (Feldman, Marecek, Quickel Jr. and Lebovitz 1972) . Except for this latter work and that of Lundquist, Ekholm and Ericson (1971) none of the above mentioned studies were carried out in models where biphasic insulin release could be observed.
It is the purpose of this work to study the effects of serotonin and its antagonists, MSM, SQ and Cy, on the basal (4.4 mM glucose) and glucose-mediated (16.6 mM glucose) first phase of insulin release from an in situ perfused rat pancreas.
The effect of serotonin and its antagonists was also studied in rats rendered hypersomatotropic by transplanting the growth hormone (GH) secreting tumor MtT-WI5. Akerblom, Martin, Garay and Moscarello (1972) have shown that 4-5 weeks after tumor implantation these rats have a 6 and 50 fold increase in insulin and GH levels respectively, but glucose levels were significantly lower (12%). In addition, the ß cells of these rats have an increased sensitivity to glucose (Martin and Akerblom 1968) and responded to continuous glucose challenge with the typical biphasic pattern of insulin release (de Bold, Bencosme and Martin 1976) . These latter authors also noted that the levels of insulin obtained were higher than those seen in normal rats.
Material and Methods

Animals and tumor inocu/ation
Normal -Female Wistar{Furth rats weighing 150-200 g were used.
Hypersomatotropic Rats -The MtT-WI5 tumor· was implan ted by sucutaneous inoculation into female Wistar/Furth rats weighing 100-130 g as reported by Garay, Akerblom and Martin (l971). Body weight was determined twice a week. Animals were used four to five weeks after implantation. At this time they weighed 250-300 g whereas at the same age normal rats weighed 150-200 g. In our laboratory the colony bearing the MtT-WI5 tumor showed a growth curve, GH**, immunoreactive insulin (IRI) and glucose levels similar to that reported by Ifkerblom et al. (1972) . All animals were fasted 18-20 hrs prior to use. . reas using a non-recycling perfusion system. At the end of a 15 min stabilization period (0 time), in which perfusion was carried out with the above medium, the gland was perfused 3 minutes longer with the same medium to obtain the basal IR! levels. During this period and for the rest of the perfusion, the perfusate was collected from the portal vein at 60 sec intervals. After 3 minutes, the glucose stimulus (16.6 mM) and the test substance were applied. Flow rates in the preparation averaged approximately 7 ml/ min.
Perfused Pancreas Preparation
Analytical Methods
Insulin levels were measured by radioimmunoassay using the Phadebas® insulin kit. Growth hormone was measured as described by Martin, J1.kerblom and Garay (1968) . Plasma glucose was measured by the glucose oxidase method using the Autoanalysee.
Statistical Analysis
The effects of serotonin and its antagonists on the first phase of IRI release were expressed as the integrated areas under
the insulin curve from 3 to 8 minutes (~IRI). Statistical comparison of the results was made using the Student's t-test. Differences were considered to be significant for p <0.05.
Chemieals
Serotonin creatinine sulfate was purchased from Calbiochem (Calif., U.S.A.) and insulin reagent kits (PhadebaS®) from Pharmacia (Montreal, P.Q., Canada). Methylsergide maleate, cyproheptadine and Squibb SQ 10,631 (batch #3) were kindIy supplied by Sandoz Pharmaceuticals (Montreal, P.Q., Canada), Merck, Sharpe and Dohme (West Point, Pa.) and Squibb (Montreal, P.Q., Canada) respectively.
ResuIts
Ellect 01 Serotonin and its Antagonists in Normal Rats
Increase in glucose concentration in the perfusate from 4.4 mM to 16.6 mM was accompanied by a considerable increase in IRI release from the pancreas ( Table 1 ) but did not significantly affect basal insulin release ( Fig. 2 , Table 1 ). Inhibition obtained with 1.0 x 10-5 M serotonin was greater than that seen with 2.3 x 10-4 M serotonin, this unexpected finding is not possible to interpret at present without a detailed dose-response study. The serotonin antagonists, MSM (1.0 x 10-4M) and Cy (2.8 x 10-9 M) effectively blocked the inhibition induced by serotonin (2.3 x 10-4 M) whereas a partial blocking effect was found with SQ (1.0 x 1O-4 M) (Fig. 3 , Table 1 ). In the presence of serotonin, only MSM significantly (p < 0.01) potentiated the glucose-media ted first phase of IRI (Fig. 3 , Table 1). In the absence of serotonin, MSM significantly (p< 0.001) enhanced the first phase of IRI release (Fig. 4 , Table 1 ). In contrast, SO and ey did not significantly potentiate the glucose-media ted IRI release (Fig. 4, Table 1 ). When the serotonin antagonists were tested at non-stimulatory glucose concentration (4.4 mM) there was a significant release of IRI by MSM and SO (Fig. 5 , Table 1 ). In both instances there was an immediate increase in insulin release followed by a rapid decrease. The IRI in the perfusate, however, remained above the basal levels until the end of the experimental period. ey did not stimulate the basal IRI release.
Effect of Serotonin and its Antaganists in Hypersomatotropic Rats
A summary and statistical analysis of the results obtained in the various experiments are given in Table  2 .
Serotonin inhibited the first phase of IRI release in tumor rats and this inhibition was apparently concentration dependent, e.g., whereas 1.0 x lO-s M inhibits the IRI release by 30%, 4.6 x 10-3 M reduced it by 80%. It should be noted that this latter serotonin concentration did not significantly alter the basal IRI release. The serotonin antagonists failed to block the inhibition induced by serotonin.
In the absence of serotonin MSM did not potentiate the glucose-media ted IRI release whereas SO and ey significantly inhibited the first phase of IRI release.
In the presence of a non-stimulatory glucose concentration MSM and SO significantly stimulated the insulin release whereas ey had no effect. It is of interest that the insulinotropic effect observed with MSM and SO du ring basal (4.4 mM glucose) conditions was similar to that found in normal rats.
Discussion
In the present study, it has been clearly demonstrated that exogenous serotonin inhibits the first phase of insulin release from the in situ perfused pancreas of normal rats. This inhibition is effectively blocked by the serotonin antagonists MSM, SO and ey. Blunting of the early peak of insulin release observed in patients with the carcinoid syndrome and its return to normal levels after lowering the circulating serotonin concentration by tumor therapy (Feldman et al. 1972 ) is consistent with these results.
The rapidity with which serotonin and its antagonists modify the first phase of insulin release strongly suggests that both of these substances might be acting at the level of the ß cell membrane since studies with islets of Langerhans (Cegrell 1968) indicate poor penetration of serotonin across "intact" cell membranes. Thist study reinforces the hypo thesis of Feldman and Lebovitz (1972) whereby exogenous serotonin may be acting at the cell membrane. The effect of exogenous serotonin on the basal insulin release is still controversial. Some authors (Te/ib et al. 1968; Gagliardino et al. 1971; Gagliardino, Nierle and Pfeiffer 1974) found that serotonin stimulates basal insulin release, while others found inhibition Quickel Jr. and Lebovitz (1972) . In contrast to the observations reported by these authors, we found that Cy did not potentiate the glucose-mediated insulin release and did not stimulate basal insulin release. Furthermore, we did observe a stimulation of basal insulin release with MSM using the same concentration as these authors. These discrepancies may be acounted for by differences in the experimental models used. Considering the insulinotropic effects observed with MSM and SQ one may speculate that intracellular serotonin could be controlling the release of insulin by acting at the ß cell membrane level rather than exerting a tonic inhibitory action on the migration of ß cell granules, as postulated by Lebovitz and Feldman (1973) . From our results it seems reasonable to hypothesize that serotonin which is stored in ß cell granules (Jaim-Etcheverry and Zieher 1968) could be released together with insulin (Bartith 1974) and by a feedback mechanism regulate the amount of insulin liberated at the ß cell membrane. Serotonin antagonists could block this regulatory mechanism resulting in the observed increase in insulin release with both high and low glucose concentration. If this hypothesis is true, one may expect to find a decreased ß cell sensitivity to serotonin in conditions characterized by basal insulin levels higher than normal and/or in those conditions with greatly augmented insulin release to insulinotropic substances such as is the case with the hypersomatotropic rat model (Akerblom et al. 1972 ).
Dur results with hypersomatotropic rats show that their ß cells have indeed a decreased sensitivi ty to serotonin. Exogenous serotonin inhibits the first phase of glucose-mediated insulin release from tumorbearing rats but to achieve the same degree of inhibition as in normal rats, a serotonin concentration 20-fold higher had to be used.
The use of serotonin antagonists in hypersomatotropic rats yielded different results than those in normal animals in that (1) MSM, SQ and Cy did not block the inhibition induced by serotonin on the glucose-mediated first phase of IRI release, (2) in the absence of exogenous serotonin, MSM did not potentiate the first phase of insulin release induced by glu- cose whereas SQ and Cy inhibited this first phase. These results can be interpreted in two ways, either changes have occurred in ß cells of hypersomatotropic rats leading to an alteration of their normal response to the serotonin antagonists or the concentration of the antagonists used were not sufficient to elicit a similar response as that obtained in normal rats. If this latter possibility proves to be correct it would appear that ß cells in these animals have a decreased sensitivity to serotonin antagonists in addition to their decreased sensitivity to serotonin. The possibility that ß cells from hypersomatotropic rats might have a decreased sensitivity to serotonin antagonists is indicated by the fact that MSM and SQ although they stimulated the IRI release in the presence of a low glucose concentration, the levels of insulin obtained were3 times lower than those seen in normal rats.
The insulinotropic effect observed with MSM and SQ in both normal and tumor-bearing rats is consistent with our earlier suggestion that these drugs appeared to act by antagonizing the action of intracellular serotonin released from ß cells.
The present study does not exclude the possibility that in both normal and hypersomatotropic rats the insulinotropic effects of the sero ton in antagonists might occur by an independent mechanism unrelated to serotonin. 
SUl!lmary
Three major lipolytic faetors, termed peaks 1, 2 and 3, according to their elution sequence from Biogel P6 columns, have been identified in duck intestinal extracts. The small molecular weight peaks 2 and 3, were even more IipolyticaIly potent on ehiek adipocytes than pancreatic glucagon; peak 1, called gut GLI, because of its cross-reactivity in a radioimmunoassay for glucagon, modified the lipolytic aetivity of peak 2 and pancreatic glucagon. It did so by modifying their capacity to stimulate eyelie AMP production.
Introduction
Duck intestinal extracts contain at least three factors which are able to modify the level of lipolysis in vitro. The two small molecular weight species, termed peaks 2 and 3, after their elution sequence from Biogel P6 colums, were found to be even more active than pancreatic glucagon (porcine or duck) which was previously considered as the primary lipolytic molecule in avies. The first peak to be eluted (likewise detected by ultraviolet absorption spectrometry), and termed gut GLI (gut glucagon-like immunoreactivity) because it cross-reacts in a non-pancreas-specific Received: 15 Sept. 1977 Accepted: 8 Jan. 1978 glucagon radioimmunoassay, reduced the amount of glycerol released by pancreatic glucagon and intestinal peak 2, but not that resulting from incubations with peak 3 ( Krug and Mialhe 1977) . This gut GLI is not of the same purity as the molecule painstakingly isolated from tons of porcine gut by Jacobson et a1. , which has been recently characterized (Jacobsort, Demandl, Moody and Sundby 1977) .
The identification of an antilipolytic molecule in the intestine was considered to be of paramount importance as birds had seemed to be devoid of such a vital regulatory factor: for, unlike in marnmals insulin is devoid of any antilipolytic activity in either "in vitro" or "in vivo" (Desbals 1972; Langslow and Haies 1971) . The present study was therefore undertaken in an attempt to clarify its mode of action. Sampies of gut GLI were incubated alone, and in the presence of the pancreatic and intestinal lipolytic species already referred to, and measurements made of the cyclic AMP and glycerol produced by chick adipocytes.
Methods
Ten to fifteen day-<>Id "Warren" chicks were killed by cervieal dis1oeation and adipocytes prepared from the leg fat pads in a 35 minutes incubation at 400 with 3 mg collagenase, 9 ml Krebs-4% albumin per gram tissue (Krug and Mialhe 1975) . G1ycerol was measured by the teehnique of Laurell et aJ. (1966) . For determinations of cyclic AMP, the reaction was stopped with 1 ml glacial aeetic acid followed by 5 minutes heating in a boiling water bath. After centrifugation (160 g) for 10 minutes, and eooling in ice. an aliquot (1 ml) of super- 
